[go: up one dir, main page]

WO1999005170A8 - RECEPTEUR β D'OESTROGENES ET ISOFORMES - Google Patents

RECEPTEUR β D'OESTROGENES ET ISOFORMES

Info

Publication number
WO1999005170A8
WO1999005170A8 PCT/US1998/015539 US9815539W WO9905170A8 WO 1999005170 A8 WO1999005170 A8 WO 1999005170A8 US 9815539 W US9815539 W US 9815539W WO 9905170 A8 WO9905170 A8 WO 9905170A8
Authority
WO
WIPO (PCT)
Prior art keywords
erβc
isoforms
methods
receptor
block
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/015539
Other languages
English (en)
Other versions
WO1999005170A1 (fr
WO1999005170A9 (fr
Inventor
Rex Denton
Rene Galien
Michele Rische-Rigon
Caroline Frasion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Priority to CA002297907A priority Critical patent/CA2297907A1/fr
Priority to JP2000504163A priority patent/JP2001510690A/ja
Priority to EP98937168A priority patent/EP1001983A1/fr
Publication of WO1999005170A1 publication Critical patent/WO1999005170A1/fr
Publication of WO1999005170A9 publication Critical patent/WO1999005170A9/fr
Publication of WO1999005170A8 publication Critical patent/WO1999005170A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne l'acide aminé et la séquence nucléotidique du gène complet du récepteur β d'oestrogène (ERβc) ainsi que les séquences de protéine associées. Au vu de cette découverte, la présente invention concerne des procédés d'identification d'agents bloquant ou augmentant la régulation transcriptionnelle induite par l'ERβ, des procédés permettant de déterminer si l'ERβc, ou ses isoformes, sont exprimés dans des tissus ou des cellules, et des procédés d'identification et d'utilisation des agents bloquant la régulation transcriptionnelle des gènes par l'ERβc, ou ses isoformes, qui, à leur tour, modulent d'autres processus biologiques et pathologiques.
PCT/US1998/015539 1997-07-28 1998-07-28 RECEPTEUR β D'OESTROGENES ET ISOFORMES Ceased WO1999005170A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002297907A CA2297907A1 (fr) 1997-07-28 1998-07-28 Recepteur beta d'oestrogenes humains
JP2000504163A JP2001510690A (ja) 1997-07-28 1998-07-28 ヒトエストロゲン受容体β
EP98937168A EP1001983A1 (fr) 1997-07-28 1998-07-28 RECEPTEUR $g(b) D'OESTROGENES ET ISOFORMES

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5386997P 1997-07-28 1997-07-28
US60/053,869 1997-07-28
US5421097P 1997-07-30 1997-07-30
US60/054,210 1997-07-30

Publications (3)

Publication Number Publication Date
WO1999005170A1 WO1999005170A1 (fr) 1999-02-04
WO1999005170A9 WO1999005170A9 (fr) 1999-03-11
WO1999005170A8 true WO1999005170A8 (fr) 1999-04-15

Family

ID=26732327

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1998/015540 Ceased WO1999005171A1 (fr) 1997-07-28 1998-07-28 Nouveau recepteur beta d'oestrogenes et ses isoformes
PCT/US1998/015539 Ceased WO1999005170A1 (fr) 1997-07-28 1998-07-28 RECEPTEUR β D'OESTROGENES ET ISOFORMES

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1998/015540 Ceased WO1999005171A1 (fr) 1997-07-28 1998-07-28 Nouveau recepteur beta d'oestrogenes et ses isoformes

Country Status (4)

Country Link
EP (2) EP1001984A1 (fr)
JP (2) JP2001510690A (fr)
CA (2) CA2298053A1 (fr)
WO (2) WO1999005171A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6222015B1 (en) 1997-09-08 2001-04-24 Merck & Co., Inc. Estrogen receptor
EP1366366B1 (fr) * 2000-05-10 2010-10-20 Signe BioPharma Inc. Compositions et methodes de diagnostic, de traitement et de prevention de cancers sensibles aux hormones steroides

Also Published As

Publication number Publication date
CA2297907A1 (fr) 1999-02-04
EP1001984A1 (fr) 2000-05-24
JP2001510690A (ja) 2001-08-07
CA2298053A1 (fr) 1999-02-04
JP2001510691A (ja) 2001-08-07
WO1999005170A1 (fr) 1999-02-04
EP1001983A1 (fr) 2000-05-24
WO1999005171A1 (fr) 1999-02-04

Similar Documents

Publication Publication Date Title
EP1092771A3 (fr) Modulateurs de transcription regulés par la tetracycline
DE69632466D1 (de) Lösung die chaotropische mittel enthält und verwendung dieser lösung in verfahren zur isolierung von dna, rna und proteinen
EP1005540A4 (fr) Proteines ikk-beta, acides nucleiques et procedes
WO2000027994A3 (fr) Sequence genomique de chlamydia pneumoniae
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
EP1757689A3 (fr) Famille de gènes mammaliens de protéines inhibant l'apoptose (iap), amorces, sondes et procédés de détection
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
EP0804609A4 (fr) NOUVEAUX GENES DE REPONSE p53
DE69808743D1 (en) Netrinrezeptoren
GB9722320D0 (en) Human cell cycle checkpoint proteins
CA2281895A1 (fr) Ikb kinases
ATE295888T1 (de) Genfallen-konstrukt zur identifizierung und isolierung von genen
IL132099A0 (en) Methods for assessing cardiovascular status and compositions for use therein
WO2000009693A3 (fr) Identification du gene responsable du phenotype de la souris 'scurfy' et de son orthologue humain
EP1005539A4 (fr) PROTEINES IKK-$g(a), ACIDES NUCLEIQUES ET PROCEDES
WO2003038055A3 (fr) Proteines impliquees dans la regulation des adipocytes et utilisations associees
WO2000008157A3 (fr) Genes humains transporteurs d'anions atnov
ZA97835B (en) Purified sr-p70 protein
WO1999005170A8 (fr) RECEPTEUR β D'OESTROGENES ET ISOFORMES
WO2000045179A3 (fr) Bioanalyses de modulateurs sensoriels utilisant une sous-unite beta de la proteine g specifique aux cellules sensorielles
AU3205600A (en) Method and kit for early cancer prediction
NZ518458A (en) Isolate DNA polymerase lambda and uses thereof
MXPA02000293A (es) Isoformas de la amp ciclico fosfodiesterasa y metodos de uso.
AU2002335491A1 (en) Test system for determining gene toxicities
AUPO780297A0 (en) Determination of genetic sex in equine species by analysis of y-chromosomal DNA sequences

Legal Events

Date Code Title Description
ENP Entry into the national phase in:

Ref country code: US

Ref document number: 1998 200963

Date of ref document: 19981130

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1-54, DESCRIPTION, REPLACED BY NEW PAGES 1-61; PAGES 55-57, CLAIMS, REPLACED BY NEW PAGES 62-64; AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY (WITH AN UPDATED VERSION OF THE PAMPHLET FRONT PAGE)

AK Designated states

Kind code of ref document: C1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase in:

Ref document number: 2297907

Country of ref document: CA

Ref country code: CA

Ref document number: 2297907

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998937168

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998937168

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09463593

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1998937168

Country of ref document: EP